Weight loss and exercise program for older Veterans recovering from COVID-19

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research examines how obesity and Post-COVID Conditions (PCC) affect physical functioning and health-related quality of life in older Veterans. It aims to evaluate the impact of a 12-week weight loss intervention, which includes dietary changes and exercise, on reducing inflammation and promoting recovery from PCC. The study will involve a randomized controlled trial comparing the effects of weight loss versus weight stability in Veterans with varying degrees of post-COVID symptoms. The goal is to better understand the relationship between obesity, inflammation, and recovery from PCC.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. U.S. Veteran
2. Self-reported COVID-19 naïve or COVID-19 \> 90 days ago for lean and obese PCC naïve or documented COVID-19 for the lean and obese PCC groups (At least one PCC symptom \>4 weeks)
3. Body Mass Index: 19-25 or 30-50 kg/m2

Exclusion Criteria:

1. Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments
2. Active inflammatory, COVID-19, autoimmune, infectious, hepatic (LFTs \> 2.5 x WNL), renal (eGFR\<45), gastrointestinal, malignant, and psychiatric disease
3. Uncontrolled diabetes (HbA1c \>10% or the current use of insulin)
4. Weight change within the past month of \>5 kg
5. Self-reported alcohol or drug abuse
6. Anti-coagulant medication usage

Where it's running

• Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
  Baltimore, Maryland, United States Recruiting
• South Texas Health Care System, San Antonio, TX
  San Antonio, Texas, United States Recruiting

Study contacts

• Principal investigator: Alice S. Ryan, PhD — Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
• Study coordinator: Kristina Marcus, MS
• Email: kristina.marcus@va.gov
• Phone: (410) 605-7000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.